Omnicell (NASDAQ:OMCL) has been assigned a $82.00 price objective by equities research analysts at Sidoti in a research note issued to investors on Friday, TipRanks reports. The firm currently has a “hold” rating on the stock. Sidoti’s price target would indicate a potential upside of 16.36% from the stock’s current price.
OMCL has been the subject of a number of other reports. TheStreet raised Omnicell from a “c+” rating to a “b” rating in a research note on Thursday. Zacks Investment Research raised Omnicell from a “hold” rating to a “buy” rating and set a $79.00 price objective for the company in a research note on Monday, July 29th. ValuEngine cut Omnicell from a “buy” rating to a “hold” rating in a research note on Wednesday, September 4th. BidaskClub raised Omnicell from a “hold” rating to a “buy” rating in a research note on Saturday, October 12th. Finally, Craig Hallum raised Omnicell from a “hold” rating to a “buy” rating and set a $85.00 price objective for the company in a research note on Friday, July 26th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $80.33.
NASDAQ:OMCL traded down $0.53 on Friday, reaching $70.47. The company’s stock had a trading volume of 34,418 shares, compared to its average volume of 215,475. Omnicell has a 12-month low of $56.96 and a 12-month high of $92.59. The company has a quick ratio of 1.54, a current ratio of 2.03 and a debt-to-equity ratio of 0.10. The firm has a market cap of $3.15 billion, a price-to-earnings ratio of 46.06, a price-to-earnings-growth ratio of 2.96 and a beta of 1.12. The stock has a 50 day moving average price of $73.55 and a 200 day moving average price of $76.77.
Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, October 24th. The company reported $0.76 EPS for the quarter, beating the Zacks’ consensus estimate of $0.71 by $0.05. Omnicell had a return on equity of 12.23% and a net margin of 6.28%. The company had revenue of $228.80 million for the quarter, compared to the consensus estimate of $231.86 million. During the same quarter in the previous year, the business earned $0.63 earnings per share. The company’s revenue for the quarter was up 12.0% on a year-over-year basis. Equities research analysts expect that Omnicell will post 2.05 EPS for the current fiscal year.
In other news, EVP Scott Peter Seidelmann sold 1,300 shares of Omnicell stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $75.17, for a total value of $97,721.00. Following the completion of the sale, the executive vice president now directly owns 26,333 shares of the company’s stock, valued at $1,979,451.61. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Randall A. Lipps sold 25,926 shares of Omnicell stock in a transaction on Monday, October 21st. The shares were sold at an average price of $78.03, for a total value of $2,023,005.78. Following the completion of the sale, the chief executive officer now directly owns 128,487 shares of the company’s stock, valued at $10,025,840.61. The disclosure for this sale can be found here. Insiders sold 40,010 shares of company stock valued at $3,064,563 over the last ninety days. Insiders own 2.77% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in OMCL. Whittier Trust Co. acquired a new position in Omnicell during the 2nd quarter worth $26,000. Tower Research Capital LLC TRC acquired a new position in Omnicell during the 2nd quarter worth $40,000. Winslow Evans & Crocker Inc. grew its stake in Omnicell by 2,876.2% during the 2nd quarter. Winslow Evans & Crocker Inc. now owns 1,250 shares of the company’s stock worth $108,000 after purchasing an additional 1,208 shares in the last quarter. C M Bidwell & Associates Ltd. grew its stake in Omnicell by 164.4% during the 2nd quarter. C M Bidwell & Associates Ltd. now owns 1,375 shares of the company’s stock worth $118,000 after purchasing an additional 855 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Omnicell by 22.6% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,694 shares of the company’s stock worth $195,000 after purchasing an additional 496 shares in the last quarter. 97.92% of the stock is owned by hedge funds and other institutional investors.
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.